What do systematic reviews say?

Ketoconazole 400 mg vs Ketoconazole 200 mg

• Interventions for preventing oral candidiasis for patients with cancer receiving treatment 2007 · Cochrane All outcomes
  1 study (Scrimgeour 1985); no patient experienced oral candidiasis, not estimable
  1 study
  GRADE not reported

Antifungal drugs absorbed from GI tract (fluconazole, ketoconazole, itraconazole) vs placebo or no treatment

The review found no eligible studies for this question.

• Interventions for preventing oral candidiasis for patients with cancer receiving treatment 2007 · Cochrane All outcomes
  No trial reported this planned secondary outcome for any comparison in this review
  Studies not reported
  No studies found

Thymostimulin vs placebo or no treatment

Thymostimulin showed no clear difference in oral candidiasis (present) compared with placebo or no treatment; GRADE not reported.

• Interventions for preventing oral candidiasis for patients with cancer receiving treatment 2007 · Cochrane All outcomes
  RR 0.4 [0.12, 1.32]
  1 study · 35 participants
  GRADE not reported

Antifungal drugs absorbed from GI tract (fluconazole, ketoconazole, itraconazole) vs Antifungal drugs not absorbed from GI tract

Antifungal drugs absorbed from GI tract showed no clear difference in empirical antifungal treatment compared with antifungal drugs not absorbed from GI tract; GRADE not reported.

• Interventions for preventing oral candidiasis for patients with cancer receiving treatment 2007 · Cochrane All outcomes
  RR 0.89 [0.68, 1.16]
  4 studies · 1031 participants
  GRADE not reported

Itraconazole vs Fluconazole

• Interventions for preventing oral candidiasis for patients with cancer receiving treatment 2007 · Cochrane All outcomes
  2 studies, 232 participants; effect not estimable
  2 studies · 232 participants
  GRADE not reported

Norfloxacin plus amphotericin B vs Amphotericin B

Norfloxacin plus amphotericin B showed no clear difference in systemic fungal infection compared with amphotericin B; GRADE not reported.

• Interventions for preventing oral candidiasis for patients with cancer receiving treatment 2007 · Cochrane All outcomes
  RR 0.67 [0.2, 2.23]
  1 study · 106 participants
  GRADE not reported

Antifungal drugs partially absorbed from GI tract (miconazole, clotrimazole) vs placebo or no treatment

Antifungal drugs partially absorbed from GI tract (miconazole,… led to lower oral candidiasis (present) compared with placebo or no treatment; GRADE not reported.

• Interventions for preventing oral candidiasis for patients with cancer receiving treatment 2007 · Cochrane All outcomes
  RR 0.16 [0.06, 0.46]
  4 studies · 292 participants
  GRADE not reported

Antifungal drugs absorbed from GI tract (fluconazole, ketoconazole, itraconazole) vs placebo or no treatment

The review found no eligible studies for this question.

• Interventions for preventing oral candidiasis for patients with cancer receiving treatment 2007 · Cochrane All outcomes
  No trial reported this planned secondary outcome for any comparison in this review
  Studies not reported
  No studies found

Antifungal drugs absorbed from GI tract (fluconazole, ketoconazole, itraconazole) vs Antifungal drugs not absorbed from GI tract

Antifungal drugs absorbed from GI tract showed no clear difference in systemic fungal infection compared with antifungal drugs not absorbed from GI tract; GRADE not reported.

• Interventions for preventing oral candidiasis for patients with cancer receiving treatment 2007 · Cochrane All outcomes
  RR 0.59 [0.33, 1.06]
  8 studies · 2103 participants
  GRADE not reported

Itraconazole vs Fluconazole

Itraconazole showed no clear difference in death associated with fungal infection compared with fluconazole; GRADE not reported.

• Interventions for preventing oral candidiasis for patients with cancer receiving treatment 2007 · Cochrane All outcomes
  RR 0.14 [0.01, 2.73]
  1 study · 202 participants
  GRADE not reported

Itraconazole vs Fluconazole

Itraconazole showed no clear difference in good compliance compared with fluconazole; GRADE not reported.

• Interventions for preventing oral candidiasis for patients with cancer receiving treatment 2007 · Cochrane All outcomes
  RR 0.95 [0.85, 1.05]
  1 study · 202 participants
  GRADE not reported

Antifungal drugs partially absorbed from GI tract (miconazole, clotrimazole) vs placebo or no treatment

Antifungal drugs partially absorbed from GI tract (miconazole,… showed no clear difference in empirical antifungal treatment compared with placebo or no treatment; GRADE not reported.

• Interventions for preventing oral candidiasis for patients with cancer receiving treatment 2007 · Cochrane All outcomes
  RR 3.38 [0.15, 77.12]
  1 study · 32 participants
  GRADE not reported

Antifungal drugs absorbed from GI tract (fluconazole, ketoconazole, itraconazole) vs Antifungal drugs not absorbed from GI tract

Antifungal drugs absorbed from GI tract showed no clear difference in death associated with fungal infection compared with antifungal drugs not absorbed from GI tract; GRADE not reported.

• Interventions for preventing oral candidiasis for patients with cancer receiving treatment 2007 · Cochrane All outcomes
  RR 1.25 [0.38, 4.13]
  3 studies · 981 participants
  GRADE not reported

Nystatin vs Chlorhexidine plus nystatin

Nystatin showed no clear difference in oral candidiasis (present) compared with chlorhexidine plus nystatin; GRADE not reported.

• Interventions for preventing oral candidiasis for patients with cancer receiving treatment 2007 · Cochrane All outcomes
  RR 1.82 [0.73, 4.54]
  1 study · 50 participants
  GRADE not reported

Antifungal drugs not absorbed from GI tract vs placebo or no treatment

Antifungal drugs not absorbed from GI tract showed no clear difference in death associated with fungal infection compared with placebo or no treatment; GRADE not reported.

• Interventions for preventing oral candidiasis for patients with cancer receiving treatment 2007 · Cochrane All outcomes
  RR 0.16 [0.01, 2.95]
  1 study · 51 participants
  GRADE not reported

Chlorhexidine vs Nystatin

Chlorhexidine showed no clear difference in oral candidiasis (present) compared with nystatin; GRADE not reported.

• Interventions for preventing oral candidiasis for patients with cancer receiving treatment 2007 · Cochrane All outcomes
  RR 0.89 [0.36, 2.21]
  1 study · 34 participants
  GRADE not reported

Antifungal drugs absorbed from GI tract (fluconazole, ketoconazole, itraconazole) vs placebo or no treatment

The review found no eligible studies for this question.

• Interventions for preventing oral candidiasis for patients with cancer receiving treatment 2007 · Cochrane All outcomes
  No trial reported this planned secondary outcome for any comparison in this review
  Studies not reported
  No studies found

Antifungal drugs absorbed from GI tract (fluconazole, ketoconazole, itraconazole) vs Antifungal drugs not absorbed from GI tract

Antifungal drugs absorbed from GI tract led to higher good compliance compared with antifungal drugs not absorbed from GI tract; GRADE not reported.

• Interventions for preventing oral candidiasis for patients with cancer receiving treatment 2007 · Cochrane All outcomes
  RR 1.05 [1.03, 1.08]
  1 study · 820 participants
  GRADE not reported

Nystatin vs placebo or no treatment

Nystatin showed no clear difference in oral candidiasis (present) compared with placebo or no treatment; GRADE not reported.

• Interventions for preventing oral candidiasis for patients with cancer receiving treatment 2007 · Cochrane All outcomes
  RR 0.92 [0.78, 1.08]
  3 studies · 153 participants
  GRADE not reported

Nystatin vs Natamycin

Nystatin showed no clear difference in oral candidiasis (present) compared with natamycin; GRADE not reported.

• Interventions for preventing oral candidiasis for patients with cancer receiving treatment 2007 · Cochrane All outcomes
  RR 1.07 [0.83, 1.37]
  1 study · 28 participants
  GRADE not reported